IntelligentMDx Names Maurice Exner, Ph.D. Vice President of Research and Development
CAMBRIDGE, Mass., Dec. 19, 2012 /PRNewswire -- IntelligentMDx (IMDx) is pleased to announce that Maurice Exner , Ph.D., has joined IMDx as Vice President of Research and Development.
Formerly serving as Vice President of R&D at Focus Diagnostics, a wholly owned subsidiary of Quest Diagnostics Incorporated, Dr. Exner brings over a decade of experience in IVD product development to IMDx. While at Focus, Dr. Exner played an integral role in all aspects of IVD product development, including new technology development, manufacturing transfer, and regulatory compliance.
Dr. Exner has a record of involvement in the production and launch of over 17 CE-marked products, 8 FDA-cleared products, and 40 analyte specific reagents for targets in infectious disease and molecular genetics. Dr. Exner will utilize his industry experience and strategic vision to guide product development and commercialization efforts at IMDx.
"We are delighted to welcome a globally recognized thought leader in the clinical diagnostics industry to our team," says Dr. Alice Jacobs Nesselrodt , Chairman and CEO of IMDx. "His expertise will be a great addition to IMDx as we continue to expand our product portfolio."
Based in Cambridge, MA, USA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.
Contact: Renda Hawwa, 1-617-871-6405, email@example.com
More by this Source
IntelligentMDx gibt CE-Kennzeichnung eines Tests zum Nachweis und zur Differenzierung von Influenza A, Influenza B und respiratorischem Synzytialvirus in Echtzeit-System Abbott m2000 bekannt
Apr 15, 2013, 08:28 ET
IntelligentMDx annonce l'obtention de l'homologation CE pour son test de détection et de différenciation de la grippe A, de la grippe B et du virus respiratoire syncytial employé dans le cadre du système m2000 RealTime d'Abbott
Apr 15, 2013, 08:28 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.